Botulinum toxin (Dysport) treatment of the spastic gastrocnemius muscle in children with cerebral palsy: a randomized trial comparing two injection volumes

Abstract

Objective: To compare the effect of equivalent doses in two different volumes of botulinum toxin type A (Dysport) on gastrocnemius spasticity.

Design: Single-blind, randomized, controlled trial.

Setting: Hospital rehabilitation department

Subjects: Twenty-two children with spastic diplegic or quadriplegic cerebral palsy.

Intervention: High (500 U/5 mL) and low (500 U/1 mL)-volume preparations of Dysport were injected into the gastrocnemius muscles, each child randomly receiving one preparation in the right and the other in the left leg.

Main measures: Dynamic ankle joint range of motion (ROM), passive ROM of the ankle joint, modified Ashworth Scale scores, and the areas of the compound muscle action potential assessed before treatment and at four and eight weeks post treatment.

Results: Both legs improved significantly. The mean (SD) improvements between baseline and the end of follow-up were 19.7 (10.83) degrees for dynamic ROM, 8.4 (9.19) degrees for passive ROM, -1.3 (0.6) for modified Ashworth Scale scores, and -9.4 (11.41) mV-ms for compound muscle action potential in the high-volume group; and 13.5 (10.45) degrees for dynamic ROM, 7.4 (7.88) for passive ROM, -0.9 (0.5) for modified Ashworth Scale scores, and -5.9 (7.50) mV-ms for areas of compound muscle action potential in the low-volume group. The high-volume preparation yielded significantly greater improvement in dynamic ROM (P<0.001), muscle tone (P < 0.001), and lower compound muscle action potential area (P = 0.006).

Conclusions: A high-volume preparation of Dysport is more effective than a low volume in reducing spasticity in the gastrocnemius muscle.

Get full access to this article

View all access options for this article.

References

Park ES , Park CI , Chang HC , Park CW , Lee DS The effect of botulinum toxin type A injection into the gastrocnemius muscle on sit-to-stand transfer in children with spastic diplegic cerebral palsy . Clin Rehabil 2006; 20: 668-74.

Baker R. , Jasinski M. , Maciag-Tymecka I. et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study . Dev Med Child Neurol 2002; 44: 666-75.

Sutherland DH , Kaufman KR , Wyatt MP , Chambers HG , Mubarak SJ Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 1999; 10: 1-9.

Corry IS , Cosgrove AP , Duffy CM , McNeill S. , Taylor TC , Graham HK Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 1998; 18: 304-11.

Koman LA , Mooney JF III , Smith BP , Walker F. , Leon JM Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000; 20: 108-15.

Rosales RL , Bigalke H. , Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006; 13(suppl 1): 2-10.

Greene P. , Fahn S. , Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis . Mov Disord 1994; 9: 213-17.

Kim HS , Hwang JH , Jeong ST et al. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 2003; 45: 200-206.

Shaari CM , Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 1993; 16: 964-69.

10.

Francisco GE , Boake C. , Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil 2002; 81: 355-63.

11.

Lee LR , Chuang YC , Yang BJ , Hsu MJ , Liu YH Botulinum toxin for lower limb spasticity in children with cerebral palsy: a single-blinded trial comparing dilution techniques. Am J Phys Med Rehabil 2004; 83: 766-73.

12.

Gracies J-M. , Weisz DJ , Yang BY , Flanagan S. , Simpson DM Impact of botulinum toxin type A (BTX-A) dilution and endplate targeting technique in upper limb spasticity. Ann Neurol 2002; 52: S87.

13.

Bakheit AM Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centres. Eur J Neurol 2003; 10: 415-19.

14.

Bang MS , Chung SG , Kim SB , Kim SJ Change of dynamic gastrocnemius and soleus muscle length after block of spastic calf muscle in cerebral palsy. Am J Phys Med Rehabil 2002; 81: 760-64.

15.

Carpenter EB , Seitz DG Intramuscular alcohol as an aid in management of spastic cerebral palsy. Dev Med Child Neurol 1980; 22: 497-501.

16.

Bohannon RW , Smith MB Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987 ; 67: 206-207.

17.

Polak F. , Morton R. , Ward C. , Wallace WA , Doderlein L. , Siebel A. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2002; 44: 551-55.

18.

Hsu TS , Dover JS , Arndt KA Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004; 140: 1351-54.

19.

Bigalke H. , Wohlfarth K. , Irmer A. , Dengler R. Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol 2001; 168: 162-70.

20.

Aoki KR , Ranoux D. , Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol 2006; 13(suppl 4): 10-19.

21.

Kinnett D. Botulinum toxin A injections in children: technique and dosing issues. Am J Phys Med Rehabil 2004; 83: S59-64.

22.

Francisco GE Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil 2004; 83: S30-37.

23.

Kranz G. , Sycha T. , Voller B. , Gleiss A. , Schnider P. , Auff E. Pain sensation during intradermal injections of three different botulinum toxin preparations in different doses and dilutions. Dermatol Surg 2006; 32: 886-90.

24.

Smith SJ , Ellis E. , White S. , Moore AP A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000; 14: 5-13.

25.

Cosgrove AP , Corry IS , Graham HK Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994; 36: 386-96.

26.

Flett PJ , Stern LM , Waddy H. , Connell TM , Seeger JD , Gibson SK Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Paediatr Child Health 1999; 35: 71-77.

27.

Pandyan AD , Vuadens P. , van Wijck FM , Stark S. , Johnson GR , Barnes MP Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population . Clin Rehabil 2002; 16: 654-60.

28.

Denislic M. , Meh D. Botulinum toxin in the treatment of cerebral palsy. Neuropediatrics 1995; 26: 249-52.

29.

Eames NW , Baker R. , Hill N. , Graham K. , Taylor T. , Cosgrove A. The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol 1999; 41: 226-32.

30.

Tardieu C. , Lacert P. , Lombard M. , Truscelli D. , Tardieu G. H reflex and recovery cycle in spastic and normal children: intra- and inter-individual and inter-groups comparisons. Arch Phys Med Rehabil 1977; 58: 561-67.

31.

Ubhi T. , Bhakta BB , Ives HL , Allgar V. , Roussounis SH Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000; 83: 481-87.

32.

Sloop RR , Escutin RO , Matus JA , Cole BA , Peterson GW Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology 1996; 46: 1382-86.

33.

Hamjian JA , Walker FO Serial neurophysiological studies of intramuscular botulinum-A toxin in humans . Muscle Nerve 1994; 17: 1385-92.

34.

Ubhi T. Treatment of paediatric cerebral palsy with Dysport. Hosp Med 2000; 61: 718-21.